PART I Overview A New Type of Biopharmaceutical Company BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory appro...
expected 2026-11-09
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-24 | 2025-12-31 | 0001743881-26-000009 | EDGAR | 152K words |
| 2025-02-20 | 2024-12-31 | 0000950170-25-024119 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018811 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-004145 | EDGAR | — |
| 2022-02-25 | 2021-12-31 | 0000950170-22-002030 | EDGAR | — |
| 2021-02-25 | 2020-12-31 | 0001564590-21-008969 | EDGAR | — |
| 2020-03-03 | 2019-12-31 | 0001564590-20-008260 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-10 | 2026-06-30 | 0001743881-26-000027 | EDGAR | — |
| 2025-10-29 | 2025-09-30 | 0001743881-25-000012 | EDGAR | 50K words |
| 2025-08-05 | 2025-06-30 | 0000950170-25-103192 | EDGAR | — |
| 2025-04-29 | 2025-03-31 | 0000950170-25-060314 | EDGAR | — |
| 2024-11-12 | 2024-09-30 | 0000950170-24-124577 | EDGAR | — |
| 2024-08-01 | 2024-06-30 | 0000950170-24-089326 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-052165 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-058255 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037977 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017812 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021936 | EDGAR | — |
| 2022-08-04 | 2022-06-30 | 0000950170-22-014824 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-10 | 0001743881-26-000026 | EDGAR | — |
| 2026-07-22 | 0001140361-26-029291 | EDGAR | — |
| 2026-03-30 | 0001140361-26-011991 | EDGAR | 1K words |
| 2026-02-24 | 0001743881-26-000008 | EDGAR | — |
| 2026-02-12 | 0001140361-26-004995 | EDGAR | — |
| 2026-01-21 | 0001140361-26-001843 | EDGAR | — |
| 2026-01-12 | 0001140361-26-000971 | EDGAR | — |
| 2025-10-29 | 0001140361-25-039705 | EDGAR | — |
| 2025-10-29 | 0001743881-25-000010 | EDGAR | — |
| 2025-10-27 | 0001140361-25-039463 | EDGAR | — |
141 total filings indexed. 112 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001743881 |
| Ticker | BBIO |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Website | https://www.bridgebio.com |
| Listed | 2019-06-27 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BBIO (~200 tokens, structured JSON with cryptographic provenance)